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Few studies have evaluated the health consequences
of antimicrobial-resistant Salmonella strains associated
with outbreaks. Among 32 outbreaks occurring in the
United States from 1984 to 2002, 22% of 13,286 persons in
10 Salmonella-resistant outbreaks were hospitalized, com-
pared with 8% of 2,194 persons in 22 outbreaks caused by
pansusceptible Salmonella strains (p<0.01).
N
ontyphoidal Salmonella strains are a frequent cause of
foodborne disease outbreaks in the United States; they
account for ≈13% of outbreaks reported to the Centers for
Disease Control and Prevention (CDC) from 1993 to 1997
(1). Antimicrobial resistance is common among salmonel-
lae and has been increasing, particularly in Salmonella
enterica serotype Typhimurium, the most common
Salmonella serotype (2,3). In the 1990s, a strain of S.
Typhimurium resistant to ampicillin, chloramphenicol,
streptomycin, sulfonamides, and tetracycline (R-type
ACSSuT) emerged in the United States and Europe; most of
these isolates were phage definitive type 104 (DT104) (2).
Antimicrobial therapy is not required for most
Salmonella infections, but it may be lifesaving in patients
with or at risk for extraintestinal infection (4). Increasing
levels of antimicrobial resistance are concerning because
treatment may fail if the infecting strain of Salmonella is
resistant to the prescribed agent (5). Also, when the pro-
portion of Salmonella strains that are resistant increases,
the total prevalence of human Salmonella infections
increases (6). Resistant salmonellae preferentially cause
illness in persons who take antimicrobial drugs for medical
conditions unrelated to Salmonella infection (7–9).
One previous study has formally evaluated the human
health consequences of antimicrobial-resistant Salmonella
strains associated with outbreaks. In 1984, Holmberg et al.
reviewed CDC investigations conducted from 1973 to
1983 to determine the rate of hospitalization and death in
outbreaks caused by antimicrobial-resistant salmonellae
compared with outbreaks caused by pansusceptible salmo-
nellae (10). Because the epidemiology of both Salmonella
infections and antimicrobial resistance has changed in the
past 20 years, we repeated this analysis for outbreaks
investigated from 1984 to 2002. 
The Study
We reviewed final reports of nontyphoidal Salmonella
outbreaks investigated by CDC from 1984 to 2002. We
excluded outbreaks that occurred in a healthcare setting or
outside the United States, including on cruise ships. When
antimicrobial susceptibility was not recorded in the final
report, we searched CDC microbiology records for suscep-
tibility test results on isolates collected as part of the out-
break. Outbreaks were only included if susceptibility data
were available for >1 isolate. Because different laborato-
ries performed susceptibility testing, the antimicrobial
agents tested and the methods used varied between out-
breaks. We classified outbreaks as resistant when the out-
break strain was resistant to >1 antimicrobial agent; other
outbreaks were considered pansusceptible. Outbreaks
caused by resistant strains were additionally classified as
R-type AC/KSSuT when the outbreak strain was at least
resistant to ampicillin, chloramphenicol or kanamycin,
streptomycin, sulfamethoxazole, and tetracycline.
Outbreaks were additionally classified as resistant to a
clinically important agent when the outbreak strain was at
least resistant to ampicillin, trimethoprim-sulfamethoxa-
zole, aminoglycosides, fluoroquinolones, or a third-gener-
ation cephalosporin.
Data from the final investigative reports were used for
the analysis. When analyzing data according to outbreaks,
we calculated the medians for percentage hospitalized and
percentage who died and compared medians with the
Wilcoxon rank-sum test. When analyzing data according
to ill persons, we pooled data from the reports, calculated
proportions, and compared proportions with chi-square or,
when appropriate, Fisher exact test. The denominators for
percentage hospitalized and died varied depending on the
number of persons in whom outcome data were ascer-
tained. All p values were 2-tailed. Data were analyzed by
using SAS v.9 (SAS Institute, Cary, NC, USA). 
From 1984 to 2002, CDC investigated 48 community
outbreaks of nontyphoidal Salmonella strains in the United
States. Of these, 47 (98%) had a final report available for
review (online Appendix Table, available at http://www.
cdc.gov/ncidod/eid/vol11no06/04-1231_app.htm). We
restricted our analyses to the 39 (83%) outbreaks in which
data about antimicrobial susceptibility were available.
These 39 outbreaks affected 23,206 persons. The largest
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Typhimurium infection associated with milk consumption
developed in 16,659 persons (11).
Strains from 11 (28%) outbreaks were resistant, and 28
(72%) were pansusceptible. The 11 outbreaks caused by
resistant strains involved 18,698 persons. Of these 11 out-
breaks, 7 (64%), involving 17,182 persons, had strains that
were at least R-type AC/KSSuT, and 9 (82%), involving
17,919 persons, had strains that were resistant to a clinical-
ly important agent.
Hospitalization data were available for 32 outbreaks
involving 21,702 ill persons. The hospitalization rates
were higher for each type of outbreak caused by resistant
salmonellae compared with outbreaks caused by suscepti-
ble salmonellae (p<0.01 for each comparison) (Table). To
account for differences in the size of outbreaks, we com-
pared the median proportion of persons hospitalized and
compared hospitalization rates after excluding a large
Salmonella outbreak that occurred in 1985. The median
proportion hospitalized for each type of outbreak caused
by resistant strains (26%) was >2.5 times higher than the
median proportion hospitalized for outbreaks caused by
pansusceptible strains (10%, p<0.05 for all resistance pat-
terns). The difference in hospitalization rates between out-
breaks caused by resistant and susceptible strains was
similar after we excluded the large 1985 outbreak of resist-
ant S. Typhimurium, in which the percentage hospitalized
was 22%. The results also remained similar after excluding
S. Enteritidis outbreaks, in which rates of hospitalization
and isolate resistance were low. 
Mortality data were available for 24 outbreaks involv-
ing 21,927 persons. Agreater proportion of persons died in
resistant outbreaks than in pansusceptible outbreaks, but
the difference was not significant (0.1% in outbreaks
caused by resistant strains vs. 0.06% in outbreaks caused
by pansusceptible strains, p = 0.57) (Table).
The 8 outbreaks in which no susceptibility data were
available involved 1,914 ill persons. Three (38%) outbreaks
were due to S. Enteritidis and 2 (25%) to S. Typhimurium.
In the 6 outbreaks for which hospitalization data were
available, 70 (20%) of 353 persons were hospitalized. In
the 4 outbreaks for which mortality data were available, 7
(0.4%) of 1,708 persons died.
Conclusions
Outbreaks caused by antimicrobial-resistant, nonty-
phoidal salmonellae were associated with an increased rate
of hospitalization compared with outbreaks caused by pan-
susceptible salmonellae. The results were similar regard-
less of the definition of resistance used. This association
has been found previously in studies of sporadic illness
(12,13).
Several possible mechanisms may explain the higher
hospitalization rate. Persons who take antimicrobial drugs
for reasons unrelated to gastroenteritis have an increased
risk of developing antimicrobial-resistant Salmonella
infections; such patients may be taking antimicrobial
drugs because they have medical conditions that increase
their risk for hospitalization (7–9). We doubt that this
explains the differential hospitalization rate observed in
our study, because the outbreaks we studied occurred in
diverse community settings. A second explanation for the
higher hospitalization rate is that persons with resistant
Salmonella infections may fail empiric antimicrobial
treatment, and their physicians subsequently hospitalize
them for inpatient therapy. A third explanation is that
resistant salmonellae may be more virulent because of
some unknown factor. In the United States, resistant sal-
monellae are more often associated with hospitalization
and bloodstream infection compared to pansusceptible
salmonellae (13). In Canada and Denmark, studies have
also found excess death rates associated with resistant
Salmonella infection (14,15). In England and Wales, a
study found no association between resistance and blood-
stream infection, but that study had substantial limita-
tions, including the failure to use pansusceptible
salmonellae as a referent group and the failure to adjust
for confounders, such as age (16).
Since the review of Salmonella outbreaks published in
1984, several changes have occurred in the epidemiology
DISPATCHES
944 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005of antimicrobial-resistant salmonellae. First, S.
Typhimurium DT104 has emerged as a cause of antimicro-
bial-resistant Salmonella infections. Five outbreaks in this
study were caused by S. Typhimurium with R-type
AC/KSSuT; isolates with this resistance pattern are often
DT104 (2,17). The hospitalization rate was higher in these
5 outbreaks (median proportion hospitalized: 17%) than in
3 outbreaks caused by pansusceptible S. Typhimurium,
which suggests that resistance or related factors, rather
than just serotype, contribute to the differential rates of
hospitalization. Second, a strain of S. Newport resistant to
at least 9 agents and with diminished susceptibility to cef-
triaxone recently emerged in the United States; 1 outbreak
in this review was caused by this strain and had a hospital-
ization rate greater than that seen in most other resistant
outbreaks (18). Third, S. Enteritidis has emerged as a fre-
quent cause of foodborne outbreaks (19). S. Enteritidis
strains are infrequently resistant to antimicrobial agents,
and in this review, S. Enteritidis outbreaks were associated
with low hospitalization rates. Excluding S. Enteritidis
outbreaks did not change the results of our analysis.
The previous analysis by Holmberg et al. found that the
rate of death was significantly greater in outbreaks caused
by resistant strains (4%) compared with outbreaks caused
by pansusceptible strains (0.2%) (10). Rates of death in our
study were lower. Because this study covered a more
recent period, improvements in medical care may explain
the overall lower death rates. Studies with larger sample
sizes are needed to determine whether antimicrobial resist-
ance is associated with increased fatality rates. 
Our study has some limitations, the most important of
which is selection bias. State health departments investi-
gate hundreds of Salmonella outbreaks annually.
Occasionally, state health departments request assistance
from CDC in investigating these outbreaks. The reasons
for such requests vary but may be related to size, severity,
setting, or other features of the outbreak. While concern
about a high hospitalization rate might encourage a state
health department to request assistance from CDC in a
Salmonella outbreak, susceptibility results are usually not
known initially and are unlikely by themselves to influence
the request for assistance.
Another limitation is that our study was based on final
reports, not raw data. As a result, we were unable to adjust
for the different patient populations affected, including age,
medical condition, and other factors that could affect hospi-
talization. Excluding outbreaks that occurred in healthcare
settings may have reduced some of this bias. Adjustment
for serotype, which could also affect hospitalization rates,
was also not possible because of the small sample size.
Despite these limitations, we believe this study adds to
the weight of evidence about the health effects of antimi-
crobial-resistant salmonellae. The evidence now includes
data from outbreaks and sporadic illness in the United
States from 1970 to 2002. Data from sporadic illness and 1
outbreak is also available from Denmark (14,20). Across
these diverse studies, higher hospitalization rates are con-
sistently found in patients infected with resistant salmonel-
lae. Such data about the adverse human health effects of
resistant salmonellae should be incorporated into programs
that promote appropriate antimicrobial use in humans and
animals.
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